Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15562064 | 0.83 | KMT2A (0.49) | KMT2AMEN1APOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL28323928 | 0.82 | CYP1A2 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL31133353 | 0.82 | CYP1A2 (0.49) | KMT2AMEN1ALDH1A1RAB9ARXFP1 | |
| SCHEMBL21816086 | 0.82 | CYP1A2 (0.49) | KMT2AMEN1ALDH1A1RAB9ARXFP1 | |
| SCHEMBL31175307 | 0.82 | CYP3A4 (0.46) | MYCKMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL15175702 | 0.82 | CYP3A4 (0.46) | MYCKMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL29099977 | 0.82 | MYC (0.51) | MYCNR4A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29510565 | 0.80 | CYP1A2 (0.42) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21815977 | 0.78 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL21816405 | 0.78 | CYP1A2 (0.49) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2002022584-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | MYC 4864/4885NR4A1 4770/4885KMT2A 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.